Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. - Powerful Science for Life
Corporate - Media & Press - Arrayit Human Genome Press Release
Arrayit Speeds Analysis of the Human Genome
FOR IMMEDIATE RELEASE: April 21, 2009 9:18 ET
SUNNYVALE, CA--(Marketwire - April 21, 2009) - Arrayit Corporation (OTCBB: ARYC), a life sciences and healthcare technology leader, announces a scientific breakthrough that accelerates the analysis of the human genome. The scientific discovery by Arrayit scientists, which combines advances in surface chemistry, bioinformatics, instrumentation and microarray technology, reduces the time required to analyze the human genome from several days to less than six hours. The human genome is the DNA blueprint that contains all 25,000 genes found in the human body. Deciphering the workings of the human genome is key to diagnosing, managing and treating human illness.
Arrayit President Dr. Mark Schena, Ph.D. stated, "Speeding the rate of human genome analysis is essential for understanding the molecular and biochemical basis of diseases such as autism. We are eager to collaborate with Dr. Walker in furtherance of this goal." Dr. Stephen J. Walker, Ph.D. added, "Autism and other human diseases require sophisticated analytical tools to allow us to look comprehensively at the human genome. We are pleased to have the opportunity to use the newest technology from Arrayit in our clinical studies." Arrayit will offer the scientific breakthrough this summer as an improvement to the company's H25K whole human genome product line.
About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.
Safe Harbor Statement
Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. The factors include, but are not limited to, risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2008 and Form 10-Q for the fiscal third quarter ended September 30, 2008.
Copyright 1993-2019 Arrayit Corporation. All rights reserved.